SCI Abstract

search
+
Performance of the AASLD, EASL, and APASL Clinical Practice Guidelines in"grey zone"stages of Chinese patients with chronic hepatitis B
Performance of the AASLD, EASL, and APASL Clinical Practice Guidelines in"grey zone"stages of Chinese patients with chronic hepatitis B
Chronic hepatitis B (CHB) patients who do not meet any immunostaging criteria are categorized as the "grey zone"...
Preoperative carbohydrate loading reduces perioperative insulin resistance and hastens functional recovery of remnant liver after living donor hepatectomy: An open-label randomized controlled trial
Preoperative carbohydrate loading reduces perioperative insulin resistance and hastens functional recovery of remnant liver after living donor hepatectomy: An open-label randomized controlled trial
This study aimed to assess the effect of preoperative carbohydrate (CHO) loading on perioperative insulin resistance (PIR)...
Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled trial
Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled trial
The cut-offs of viscoelastic hemostatic assays used for guiding blood products transfusion in patients with cirrhosis unde...
Single-cell transcriptomic profiling reveals dysregulation of B-cell subset function in patients with chronic hepatitis B
Single-cell transcriptomic profiling reveals dysregulation of B-cell subset function in patients with chronic hepatitis B
The goal of this study was to investigate the immunological characteristics and potential clinical significance of B-cell ...
Impact of myosteatosis on outcomes after liver transplantation: a systematic review and meta-analysis
Impact of myosteatosis on outcomes after liver transplantation: a systematic review and meta-analysis
The impact of myosteatosis on clinical outcomes following liver transplantation (LT) remains unclear. Articles evaluating ...
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies
Functional cure is a favorable endpoint in chronic hepatitis B (CHB), yet it is rarely achieved with currently approved dr...
Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis
Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis
Achieving a “functional” cure for chronic hepatitis B (HBV) is primary goal for novel antiviral treatments. We...
Stem cells therapies for liver diseases: for current practice and future goals
Stem cells therapies for liver diseases: for current practice and future goals
Stem cell therapy has emerged as a promising approach for treating severe chronic liver diseases, including decompensated ...
Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunities
Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunities
Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent malignant neoplasm globally and represents the third-lead...
Addition of midodrine to albumin reduces the incidence of complications of large-volume paracentesis: an RCT comparing midodrine, terlipressin, and albumin
Addition of midodrine to albumin reduces the incidence of complications of large-volume paracentesis: an RCT comparing midodrine, terlipressin, and albumin
Large-volume paracentesis (LVP), a therapeutic procedure for cirrhosis patients with refractory ascites, is associated wit...
Adipokine/hepatokines profiling of fatty liver in adolescents and young adults: cross-sectional and prospective analyses of the BCAMS study
Adipokine/hepatokines profiling of fatty liver in adolescents and young adults: cross-sectional and prospective analyses of the BCAMS study
The underlying connections between obesity and non-alcoholic fatty liver disease (NAFLD) are not fully understood. One pot...
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
The international consensus to revise non-alcoholic fatty liver disease to metabolic (dysfunction)-associated fatty liver ...
Impact of graft type on outcomes following liver transplantation for primary sclerosing cholangitis
Impact of graft type on outcomes following liver transplantation for primary sclerosing cholangitis
Limited data exists regarding impact of graft type on outcomes following liver transplantation (LT) in Primary Sclerosing ...
Optimal threshold of portal pressure gradient for patients with ascites after covered TIPS: a multicentre cohort study
Optimal threshold of portal pressure gradient for patients with ascites after covered TIPS: a multicentre cohort study
Transjugular intrahepatic portosystemic shunt (TIPS) is recommended for treating recurrent and refractory ascites. However...
Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practice
Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practice
Although several therapeutic agents show efficacy in advanced hepatocellular carcinoma (HCC), biomarkers such as comprehen...
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each ...
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy
Recently, anti-programmed cell death protein-1 (anti-PD-1) and anti-PD-L1 therapies were approved for hepatocellular carci...
The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease
The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease
While metabolic-associated fatty liver disease (MAFLD) is widely recognized as a risk factor for cardiovascular disease (C...
Global, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: a trend analysis
Global, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: a trend analysis
Hepatoblastoma is the most common primary liver cancer in children, yet comprehensive understanding of its epidemiology is...
Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study
Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study
Semaglutide has shown potential liver benefits in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabet...
AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure
AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure
Acute-on-chronic liver failure (ACLF) patients with hepatorenal syndrome (HRS-AKI) have limited response to vasoconstricto...
Clinical characteristics and managements of congenital hepatic hemangioma: a cohort study of 211 cases
Clinical characteristics and managements of congenital hepatic hemangioma: a cohort study of 211 cases
Hepatic hemangiomas can be classified into three morphologic patterns: focal (congenital hepatic hemangiomas [CHHs]), mult...
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study
Regorafenib is the recommended second-line therapy for unresectable hepatocellular carcinoma (uHCC). Our study aimed to as...
Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial
Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial
Nonalcoholic fatty liver disease (NAFLD) is a common liver comorbidity with considerable global consequences. This study e...
Treating extrahepatic portal-vein obstruction with cavernoma using radiological interventions: pushing the boundaries
Treating extrahepatic portal-vein obstruction with cavernoma using radiological interventions: pushing the boundaries
Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with an...
Prophylaxis of hepatic encephalopathy: current and future drug targets
Prophylaxis of hepatic encephalopathy: current and future drug targets
Hepatic encephalopathy is described by a broad spectrum of neurological and psychiatric aberrations resulting due to advan...
Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier
Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier
Acute-on-chronic liver failure (ACLF) is a syndrome of liver failure due to an acute hepatic insult leading to liver failu...
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals
Non-alcoholic fatty liver disease (NAFLD) is present in lean people. However, the magnitude of the prognostic hepatic and ...
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD
Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis due to chronic hepatitis B virus (HBV) or...
Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer
Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer
This study conducted molecular subtyping of biliary tract cancer patients based on 19 PANoptosis-related gene signatures. ...
Load More
format_indent_increase